Reata Pharmaceuticals Inc

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates omaveloxolone and bardoxolone methyl target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Reata has active clinical, preclinical, and internal discovery programs in many significant disease areas. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the response to cellular stress in serious and life-threatening diseases that have limited or no approved therapies.

Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling (1-4). Omaveloxolone and Bardoxolone methyl are in development for the treatment of a severe neurological disorder called Friedreich’s ataxia and several forms of chronic kidney disease, respectively.

We are developing a novel class of molecules that target pathways involved in the cellular stress response. Our lead product candidate, RTA 901, and related analogs have shown promising effects in animal models of neurological disease. RTA 901 is in development for Diabetic Peripheral Neuropathic Pain.